PHD-2 Activation to Stabilize HIF-1α and FASN in Mammary Gland Cancer

Authors

  • Uma Devi Department of Pharmaceutical Sciences Faculty of Health and Medical Sciences Sam Higginbottom University of Agricultural, Technology and Sciences Naini, Allahabad- 211007 (UP), India
  • Pushpraj S Gupta Department of Pharmaceutical Sciences Faculty of Health and Medical Sciences Sam Higginbottom University of Agricultural, Technology and Sciences Naini, Allahabad- 211007 (UP), India

DOI:

https://doi.org/10.37591/rrjot.v8i3.632

Abstract

Activation of prolyl hydroxylase-2 (PHD2) has emerged as an attractive target to counteract tumor hypoxia and thereby uncontrolled cellular proliferation. We utilized an integrated strategy to identify new PHD2 activators using series of in silico tools and in vitro methods. The in silico screening helped to identify 4-ethyl-3-(4-methoxyphenyl)-2,2-dimethyl-2H-chromen-7-yl acetate (BBAP-3), [4-(7-acetyloxy-4-ethyl-2,2-dimethylchromen-3-yl)phenyl]acetate (BBAP-4), 3-(4-methoxyphenyl)-2,2,4-trimethyl-2H-chromen-7-yl acetate (BBAP-5) as an activator, who are structurally similar to KRH102140 (a known activator of PHD2). All BBAP-3, BBAP-4, and BBAP-5 were docked with enzyme PHD2. The binding energy of BBAP-3, BBAP-4, and BBAP-5 were recorded as -3.92 Kcal/mol, -3.57 Kcal/mol, and -4.59 Kcal/mol, respectively as well as all three compounds were also observed to be nonmutagenic with sufficiently high oral LD50 when evaluated through toxicity estimation software tool. The IC50 of BBAP-3, BBAP-4, and BBAP-5 were determined against tamoxifen. The BBAP-3, BBAP-4 and BBAP-5 drug did not cross 50% inhibition after 25 µM and there was also no linearity in a dose-dependent manner therefore not considered for further evaluation.

 

Keywords: fatty acid synthase, breast cancer, hypoxia-inducible factor, prolyl hydroxylase-2 (PHD2)


Cite this Article Devi U, Gupta PS. PHD-2 Activation to Stabilize HIF-1α and FASN in Mammary Gland Cancer. Research & Reviews: A Journal of Toxicology. 2018; 8(3): 28–33p.

Downloads

Published

2019-01-18

Issue

Vol. 8 No. 3 (2018)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.